cas 2353-44-8|| where to buy 3-aminopiperidine-2,6-dione

Produktname:3-aminopiperidine-2,6-dione

IUPAC Name:3-aminopiperidine-2,6-dione

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM132080-1g	in stock	ɐɐ
CM132080-5g	in stock	Ƌȷǆ
CM132080-25g	in stock	ȦſſǕ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2353-44-8 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:2353-44-8; Molekulare Formel:C5H8N2O2; Schmelzpunkt:-; SMILES-Code:NC1CCC(=O)NC1=O; Dichte:

: Katalognummer:CM132080; Molekulargewicht:128.13; Siedepunkt:334.5°C at 760 mmHg; Mdl-Nr.:MFCD11506223; Lagerung:Keep in dark place, store at 2-8°C.

: Piperidines; Piperidine is an azacycloalkane that is cyclohexane in which one of the carbons is replaced by a nitrogen. Although piperidine is a common organic compound, it is an immensely important class of compounds medicinally: the piperidine ring is the most common heterocyclic subunit among FDA approved drugs.; Piperidine,Piperidine Price; if you want to know the latest news about piperidine and piperidine price, please come to our website and get a quote for free.

: NX-2127; Existing BTK inhibitors directly bind to the active site of BTK and face challenges such as acquired resistance or incomplete responses over time. PROTAC-induced BTK degradation works as a novel alternative therapy for drug-resistant cancers. The latest journal Science publishes the identification of BTK mutations that are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Nurix Therapeutics’ TPD compound NX-2127 is a first-in-class, dual-function small-molecule protein degrader. It drives targeted BTK and transcription factor IKAROS (IKZF1/3) degradation through ubiquitination and proteasomal degradation, adding combined benefit. NX-2127 is under development of phase I clinical trials that shows promising results and a manageable safety profile for the treatment of relapsed/ refractory B-cell malignancies.